FMP
Agios Pharmaceuticals, Inc.
AGIO
NASDAQ
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
29.53 USD
0.1 (0.339%)
About
ceo
Mr. Brian M. Goff M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.agios.com
exchange
NASDAQ
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
CIK
0001439222
ISIN
US00847X1046
CUSIP
00847X104
Address
88 Sidney Street
Phone
617 649 8600
Country
US
Employee
389
IPO Date
Jul 24, 2013
Summary
CIK
0001439222
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00847X104
ISIN
US00847X1046
Country
US
Price
29.53
Beta
0.95
Volume Avg.
740.48k
Market Cap
1.64B
Shares
-
52-Week
19.8-35.5
DCF
-8.42
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-7.53
P/B
-
Website
https://www.agios.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AGIO News
It looks like there's no news available.
